Jeste Dilip V, Blazer Dan, Casey Daniel, Meeks Thomas, Salzman Carl, Schneider Lon, Tariot Pierre, Yaffe Kristine
Department of Psychiatry and Neurosciences, University of California, San Diego, CA 92161, USA.
Neuropsychopharmacology. 2008 Apr;33(5):957-70. doi: 10.1038/sj.npp.1301492. Epub 2007 Jul 18.
In elderly persons, antipsychotic drugs are clinically prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications (schizophrenia and bipolar disorder). The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia. In April 2005, the FDA, based on a meta-analysis of 17 double-blind randomized placebo-controlled trials among elderly people with dementia, determined that atypical antipsychotics were associated with a significantly (1.6-1.7 times) greater mortality risk compared with placebo, and asked that drug manufacturers add a 'black box' warning to prescribing information for these drugs. Most deaths were due to either cardiac or infectious causes, the two most common immediate causes of death in dementia in general. Clinicians, patients, and caregivers are left with unclear choices of treatment for dementia patients with psychosis and/or severe agitation. Not only are psychosis and agitation common in persons with dementia but they also frequently cause considerable caregiver distress and hasten institutionalization of patients. At the same time, there is a paucity of evidence-based treatment alternatives to antipsychotics for this population. Thus, there is insufficient evidence to suggest that psychotropics other than antipsychotics represent an overall effective and safe, let alone better, treatment choice for psychosis or agitation in dementia; currently no such treatment has been approved by the FDA for these symptoms. Similarly, the data on the efficacy of specific psychosocial treatments in patients with dementia are limited and inconclusive. The goal of this White Paper is to review relevant issues and make clinical and research recommendations regarding the treatment of elderly dementia patients with psychosis and/or agitation. The role of shared decision making and caution in using pharmacotherapy for these patients is stressed.
在老年人中,抗精神病药物在临床应用时超出了其美国食品药品监督管理局(FDA)批准的适应症(精神分裂症和双相情感障碍)范围,被用于治疗多种其他病症。老年人中抗精神病药物处方量最大的是用于治疗与痴呆相关的行为障碍。2005年4月,FDA基于对17项针对老年痴呆患者的双盲随机安慰剂对照试验的荟萃分析,确定与安慰剂相比,非典型抗精神病药物的死亡风险显著增加(1.6至1.7倍),并要求药品制造商在这些药物的处方信息中添加“黑框”警告。大多数死亡是由心脏或感染原因导致的,这也是痴呆患者总体上最常见的直接死因。临床医生、患者和护理人员在为患有精神病和/或严重激越的痴呆患者选择治疗方案时感到困惑。精神病和激越不仅在痴呆患者中很常见,还经常给护理人员带来极大困扰,并加速患者住院。与此同时,针对这一人群,除抗精神病药物外,缺乏基于证据的治疗替代方案。因此,没有足够的证据表明除抗精神病药物外的精神药物对痴呆患者的精神病或激越是一种总体有效且安全的治疗选择,更不用说更好的治疗选择了;目前FDA尚未批准任何此类药物用于治疗这些症状。同样,关于特定心理社会治疗对痴呆患者疗效的数据有限且尚无定论。本白皮书的目的是回顾相关问题,并就老年痴呆患者精神病和/或激越的治疗提出临床和研究建议。强调了共同决策的作用以及在对这些患者使用药物治疗时应谨慎的态度。